Munir T, Brown JR, O’Brien S, Barrientos JC, Barr PM, Reddy NM, et al. Remaining evaluation from RESONATE: As much as six years of follow-up on ibrutinib in sufferers with beforehand handled power lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353–63.
Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed power lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. Venetoclax–rituximab in relapsed or refractory power lymphocytic leukemia. N Engl J Med. 2018;378:1107–20.
Liang EC, Albittar A, Huang JJ, Hirayama AV, Kimble EL, Portuguese AJ, et al. Components related to long-term outcomes of CD19 CAR T-cell remedy for relapsed/refractory CLL. Blood Adv. 2023;7:6990–7005.
Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135:1650–60.
Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie Okay, Soumerai J, et al. Lisocabtagene maraleucel in power lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, part 1–2 examine. Lancet. 2023;402:641–54.
Gill S, Vides V, Frey NV, Hexner EO, Metzger S, O’Brien M, et al. Anti-CD19 CAR T cells together with ibrutinib for the remedy of power lymphocytic leukemia. Blood Adv. 2022;6:5774–85.
Frey NV, Gill S, Hexner EO, Schuster S, Nasta S, Loren A, et al. Lengthy-term outcomes from a randomized dose optimization examine of chimeric antigen receptor modified T cells in relapsed power lymphocytic leukemia. JCO. 2020;38:2862–71.
Kater A, Eradat, H, Niemann C, Offner F, Poulsen CB, Hoyer T, et al. Epcoritamab in sufferers with relapsed or refractory power lymphocytic leukemia: outcomes from the part 1b/2 EPCORE CLL-1 trial growth cohort. iwCLL; 2023 Oct 6–9; Boston, MA.
Danilov A, Tees MT, Patel Okay, Wierda WG, Patel M, Flinn IW, et al. A primary-in-human part 1 trial of NX-2127, a first-in-class Bruton’s tyrosine kinase (BTK) dual-targeted protein degrader with immunomodulatory exercise, in sufferers with relapsed/refractory B cell malignancies. Blood. 2023;142:4463.
Seymour JF, Cheah CY, Parrondo R, Thompson MC, Stevens DA, Lasica M, et al. First outcomes from a part 1, first-in-human examine of the Bruton’s tyrosine kinase (BTK) degrader Bgb-16673 in sufferers (Pts) with relapsed or refractory (R/R) B-cell malignancies (BGB-16673-101). Blood. 2023;142:4401.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL tips for prognosis, indications for remedy, response evaluation, and supportive administration of CLL. Blood. 2018;131:2745–60.
Kater AP, Harrup R, Kipps TJ, Eichhorst B, Owen CJ, Assouline S, et al. MURANO: remaining 7 12 months comply with up and retreatment evaluation in venetoclax-rituximab (VenR)-treated sufferers with relapsed/refractory power lymphocytic leukemia (R/R CLL). Hematol Oncol. 2023;41:239–42.
Seymour JF, Kipps TJ, Eichhorst BF, D’Rozario J, Owen CJ, Assouline S, et al. Enduring undetectable MRD and up to date outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022;140:839–50.
Vitale C, Salvetti C, Griggio V, Porrazzo M, Schiattone L, Zamprogna G, et al. Preexisting and treatment-emergent autoimmune cytopenias in sufferers with CLL handled with focused medicine. Blood. 2021;137:3507–17.
Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Mun Y, et al. Prognostic danger rating for sufferers with relapsed or refractory power lymphocytic leukaemia handled with focused therapies or chemoimmunotherapy: a retrospective, pooled cohort examine with exterior validations. Lancet Haematol. 2019;6:e366–74.
Shen Y, Coyle L, Kerridge I, Stevenson W, Arthur C, McKinlay N, et al. Second major malignancies in power lymphocytic leukaemia: pores and skin, strong organ, haematological and Richter’s syndrome. eJHaem. 2022;3:129–38.
Parikh SA, Leis JF, Chaffee KG, Name TG, Hanson CA, Ding W, et al. Hypogammaglobulinemia in newly recognized power lymphocytic leukemia: pure historical past, scientific correlates, and outcomes. Most cancers. 2015;121:2883–91.
Man S, Henley P. Continual lymphocytic leukaemia: the position of T cells in a B cell illness. Br J Haematol. 2019;186:220–33.
Brewer JD, Habermann TM, Shanafelt TD. Lymphoma-associated pores and skin most cancers: incidence, pure historical past, and scientific administration. Int J Dermatol. 2014;53:267–74.
Shen Y, Freeman JA, Holland J, Naidu Okay, Solterbeck A, Van Bilsen N, et al. A number of COVID-19 vaccine doses in CLL and MBL enhance immune responses with progressive and excessive seroconversion. Blood. 2022;140:2709–21.
Nguyen THO, Rowntree LC, Allen LF, Chua BY, Kedzierski L, Lim C, et al. Sturdy SARS-CoV-2 T cell responses with frequent TCRαβ motifs towards COVID-19 vaccines in sufferers with hematological malignancy impacting B cells. Cell Rep Med. 20234;4:101017.
Patten P, Prepare dinner J, Peckham N, Moss P, Phillips N, Abhishek A, et al. The influence of pausing Bruton tyrosine kinase inhibitor remedy and responsiveness of vaccination in blood most cancers sufferers: major end result consequence for the randomised enhance trial. Blood. 2023;142:1904–1904.
Strati P, Parikh SA, Chaffee KG, Kay NE, Name TG, Achenbach SJ, et al. Relationship between co-morbidities at prognosis, survival and supreme reason for loss of life in sufferers with power lymphocytic leukaemia (CLL): a potential cohort examine. Br J Haematol. 2017;178:394–402.
Albano D, Bertagna F, Dondi F, Annunziata S, Ceriani L, Giovanella L, et al. The position of 2-[18F]-FDG PET/CT in detecting Richter transformation in power lymphocytic leukemia: a scientific overview. Radiation. 2021;1:65–76.
He R, Ding W, Viswanatha DS, Chen D, Shi M, Van Dyke D, et al. PD-1 expression in power lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and huge B-cell Richter transformation (DLBCL-RT): a attribute characteristic of DLBCL-RT and potential surrogate marker for clonal relatedness. Am J Surg Pathol. 2018;42:843–54.
Klintman J, Appleby N, Stamatopoulos B, Ridout Okay, Eyre TA, Robbe P, et al. Genomic and transcriptomic correlates of Richter transformation in power lymphocytic leukemia. Blood. 2021;137:2800–16.
Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D’Rozario J, et al. Venetoclax plus rituximab in relapsed power lymphocytic leukemia: 4-year outcomes and analysis of influence of genomic complexity and gene mutations from the MURANO part III examine. JCO. 2020;38:4042–54.
Bennett R, Anderson MA, Seymour JF. Unresolved questions in collection of therapies for treatment-naïve power lymphocytic leukemia. J Hematol Oncol. 2023;16:72.
Ahn IE, Farooqui MZH, Tian X, Valdez J, Solar C, Soto S, et al. Depth and sturdiness of response to ibrutinib in CLL: 5-year follow-up of a part 2 examine. Blood. 2018;131:2357–66.
Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer Okay, et al. Frequent evolution of copy quantity alterations in CLL following first-line remedy with FC(R) is enriched with TP53 alterations: outcomes from the CLL8 trial. Leukemia. 2017;31:734–8.
Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson Okay, Lawrence MS, et al. Evolution and influence of subclonal mutations in power lymphocytic leukemia. Cell. 2013;152:714–26.
Landau DA, Solar C, Rosebrock D, Herman SEM, Fein J, Sivina M, et al. The evolutionary panorama of power lymphocytic leukemia handled with ibrutinib focused remedy. Nat Commun. 2017;8:2185.
Ahn IE, Brown JR. Concentrating on Bruton’s tyrosine kinase in CLL. Entrance Immunol. 2021;12:687458.
Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in sufferers with progressive power lymphocytic leukemia. Most cancers Discov. 2019;9:342–53.
Blombery P, Thompson ER, Nguyen T, Birkinshaw RW, Gong JN, Chen X, et al. A number of BCL2 mutations cooccurring with Gly101Val emerge in power lymphocytic leukemia development on venetoclax. Blood. 2020;135:773–7.
Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, et al. Mounted-duration ibrutinib plus venetoclax for first-line remedy of CLL: major evaluation of the CAPTIVATE FD cohort. Blood. 2022;139:3278–89.
Jain N, Croner LJ, Allan JN, Siddiqi T, Tedeschi A, Badoux XC, et al. Absence of BTK, BCL2, and PLCG2 mutations in power lymphocytic leukemia relapsing after first-line remedy with fixed-duration ibrutinib plus venetoclax. Clin Most cancers Res. 2023;1–8.
Molica S, Giannarelli D, Montserrat E. Comparability between venetoclax-based and Bruton tyrosine kinase inhibitor-based remedy as upfront remedy of power lymphocytic leukemia (CLL): a scientific overview and community meta-analysis. Clin Lymphoma Myeloma Leuk. 2021;21:216–23.
Itsara A, Solar C, Bryer E, Ahn IE, Soto S, Wang HW, et al. Lengthy-term outcomes in power lymphocytic leukemia handled with ibrutinib: 10-year follow-up of a part 2 examine. Blood. 2023;142:201.
Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, et al. ASCEND: part III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory power lymphocytic leukemia. JCO. 2020;38:2849–61.
Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos Okay, Jurczak W, et al. Zanubrutinib versus bendamustine and rituximab in untreated power lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, managed, part 3 trial. Lancet Oncol. 2022;23:1031–43.
Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Acalabrutinib versus ibrutinib in beforehand handled power lymphocytic leukemia: outcomes of the primary randomized part III trial. JCO. 2021;39:3441–52.
Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, et al. Zanubrutinib or ibrutinib in relapsed or refractory power lymphocytic leukemia. N Engl J Med. 2023;388:319–32.
Brown JR, Eichhorst BF, Lamanna N, O’Brien SM, Tam CS, Qiu L, et al. Prolonged follow-up of ALPINE randomized part 3 examine confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for remedy of relapsed/refractory power lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL). Blood. 2023;142:202–202.
Ghia P, Munir T, Burger J, Seymour J, Rogers Okay, Huang HH, et al. P645: ibrutinib for remedy of relapsed-refractory power lymphocytic leukemia: a matching-adjusted oblique comparability of three randomized part 3 trials. HemaSphere 2023;7:e78258de.
Shadman M, Tedeschi A, Mohseninejad L, Yang Okay, Lamanna N, Xu S, et al. Related efficacy of ibrutinib arms throughout ALPINE and ELEVATE-RR trials in relapsed/refractory power lymphocytic leukemia: a matching-adjusted oblique comparability. Blood. 2023;142:4655.
O’Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum Okay, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory power lymphocytic leukemia: a 5-year expertise. Blood. 2018;131:1910–9.
Del Poeta G, Biagi A, Laurenti L, Chiarenza A, Pozzo F, Innocenti I, et al. Impaired nodal shrinkage and apoptosis outline the impartial hostile end result of NOTCH1 mutated sufferers beneath ibrutinib remedy in power lymphocytic leukaemia. Haematol. 2020;106:2345–53.
Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Detailed security profile of acalabrutinib vs ibrutinib in beforehand handled power lymphocytic leukemia within the ELEVATE-RR trial. Blood. 2023;142:687–99.
Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, et al. As much as 8-year follow-up from RESONATE-2: first-line ibrutinib remedy for sufferers with power lymphocytic leukemia. Blood Adv. 2022;6:3440–50.
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Sales space AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older sufferers with untreated CLL. N Engl J Med. 2018;379:2517–28.
Kater AP, Owen C, Moreno C. Mounted-duration ibrutinib and venetoclax (I+V) versus chlormabucil plus obinutuzumab (Clb+O) for first-line (1L) power lymphocytic leukaemia: major evaluation of the part 3 GLOW examine.
Hillmen P, Pitchford A, Bloor A, Broom A, Younger M, Kennedy B, et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for sufferers with beforehand untreated power lymphocytic leukaemia (FLAIR): interim evaluation of a multicentre, open-label, randomised, part 3 trial. Lancet Oncol. 2023;24:535–52.
Sharman JP, Ghia P, Palhares De Miranda PAP, Bajwa N, Rule S, Shaw B, et al. Evaluation of ventricular arrhythmias and sudden loss of life with acalabrutinib from 5 potential scientific trials. Blood. 2023;142:4643.
Mato AR, Woyach JA, Brown JR, Ghia P, Patel Okay, Eyre TA, et al. Pirtobrutinib after a covalent BTK inhibitor in power lymphocytic leukemia. N Engl J Med. 2023;389:33–44.
Woyach JA, Brown JR, Ghia P, Roeker LE, Patel Okay, Eyre TA, et al. Pirtobrutinib in post-cBTKi CLL/SLL: ~30 months follow-up and subgroup evaluation with/with out prior BCL2i from the part 1/2 BRUIN examine. Blood. 2023;142:325.
Al-Sawaf O, Jen MH, Hess LM, Zhang J, Goebel B, Pagel JM, et al. Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated power lymphocytic leukemia: a matching-adjusted oblique comparability. Haematologica. 2023. https://haematologica.org/article/view/haematol.2023.284150.
Woyach JA, Flinn IW, Awan FT, Eradat H, Brander D, Tees M, et al. Efficacy and security of nemtabrutinib, a wild-type and C481S-mutated Bruton tyrosine kinase inhibitor for B-cell malignancies: up to date Evaluation of the open-label part 1/2 dose-expansion Bellwave-001 examine. Blood. 2022;140:7004–6.
Jain N, D’Olimpio J, gillis-Smith A, Lee ST, Shah NN, Pinilla-Ibarz J, et al. Trial in progress: a part 1b examine of AS-1763, an oral, potent and selective noncovalent BTK inhibitor, in sufferers with beforehand handled power lymphocytic leukemia/small lymphocytic lymphoma or non-Hodgkin lymphoma. Blood. 2023;142:3288–3288.
Woyach JA, Stephens DM, Brander DM, Kittai AS, Hu B, Sitlinger A, et al. Preliminary outcomes of a part 1 dose escalation examine of LP-168, a novel covalent and non-covalent next-generation inhibitor of Bruton’s tyrosine kinase. Blood. 2023;142:328.
Roeker LE, Woyach JA, Cheah CY, Coombs CC, Shah NN, Wierda WG, et al. Mounted-duration pirtobrutinib mixed with venetoclax ± rituximab in relapsed/refractory power lymphocytic leukemia: up to date outcomes, together with MRD knowledge, from the BRUIN part 1b examine. Blood. 2023;142:3269–3269.
Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Concentrating on BCL2 with venetoclax in relapsed power lymphocytic leukemia. N Engl J Med. 2016;374:311–22.
Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, et al. Venetoclax plus rituximab in relapsed or refractory power lymphocytic leukaemia: a part 1b examine. Lancet Oncol. 2017;18:230–40.
Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, et al. Efficacy of venetoclax in relapsed power lymphocytic leukemia is influenced by illness and response variables. Blood. 2019;134:111–22.
Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, et al. Venetoclax for sufferers with power lymphocytic leukemia with 17p deletion: outcomes from the total inhabitants of a part II pivotal trial. JCO. 2018;36:1973–80.
Stilgenbauer S, Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek M, et al. S146: venetoclax in sufferers with power lymphocytic leukemia with 17p deletion: 6-year follow-up and genomic analyses in a pivotal part 2 trial. HemaSphere. 2022;6:47–8.
Brown JR. Phosphatidylinositol 3 kinase δ inhibitors: current and future. Most cancers J. 2019;25:394–400.
Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, et al. The part 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132:2446–55.
Špaček M, Smolej L, Šimkovič M, Nekvindová L, Křístková Z, Brychtová Y, et al. Idelalisib plus rituximab versus ibrutinib within the remedy of relapsed/refractory power lymphocytic leukaemia: a real-world evaluation from the power lymphocytic leukemia sufferers registry (CLLEAR). Br J Haematol. 2023;202:40–7.
Lin VS, Lew TE, Handunnetti SM, Blombery P, Nguyen T, Westerman DA, et al. BTK inhibitor remedy is efficient in sufferers with CLL proof against venetoclax. Blood. 2020;135:2266–70.
Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, et al. Venetoclax for power lymphocytic leukaemia progressing after ibrutinib: an interim evaluation of a multicentre, open-label, part 2 trial. Lancet Oncol. 2018;19:65–75.
Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, et al. Evaluation of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an efficient technique. Clin Most cancers Res. 2020;26:3589–96.
Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, et al. Optimum sequencing of ibrutinib, idelalisib, and venetoclax in power lymphocytic leukemia: outcomes from a multicenter examine of 683 sufferers. Ann Oncol. 2017;28:1050–6.
Ysebaert L, Ferrant E, Dilhuydy MS, Michallet AS, Inchiappa L, Guieze R, et al. Outcomes of CLL sufferers uncovered to venetoclax+/-R after ibrutinib in France: the resist retrospective examine from the Filo-CLL Group. Blood. 2023;142:3273.
Lew TE, Bennett R, Lin VS, Whitechurch A, Handunnetti SM, Marlton P, et al. Venetoclax-rituximab is lively in sufferers with BTKi-exposed CLL, however sturdy treatment-free remissions are unusual. Blood Adv. 2024;bloodadvances.2023011327.
Ghia P, Wierda WG, Barr PM, Kipps TJ, Siddiqi T, Allan JN, et al. Relapse after first-line fastened length ibrutinib + venetoclax: excessive response charges to ibrutinib retreatment and absence of BTK mutations in sufferers with power lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with as much as 5 years of follow-up within the part 2 captivate examine. Blood. 2023;142:633–633.
Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, O’Brien SM, et al. Financial burden of power lymphocytic leukemia within the period of oral focused therapies in the US. JCO. 2017;35:166–74.
Bennett R, Thompson E, Tam C. SOHO cutting-edge updates and subsequent questions | mechanisms of resistance to BCL2 inhibitor remedy in power lymphocytic leukemia and potential future therapeutic instructions. Clin Lymphoma Myeloma Leuk. 2022;22:795–804.
Thompson MC, Harrup RA, Coombs CC, Roeker LE, Pu JJ, Choi MY, et al. Venetoclax retreatment of sufferers with power lymphocytic leukemia after a earlier venetoclax-based routine. Blood Adv. 2022;6:4553–7.
Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, et al. Acalabrutinib monotherapy in sufferers with power lymphocytic leukemia who’re illiberal to ibrutinib. Blood Adv. 2019;3:1553–62.
Shadman M, Flinn IW, Levy MY, Porter RF, Burke JM, Zafar SF, et al. Zanubrutinib in sufferers with beforehand handled B-cell malignancies illiberal of earlier Bruton tyrosine kinase inhibitors within the USA: a part 2, open-label, single-arm examine. Lancet Haematol. 2023;10:e35–45.
Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, et al. Part II examine of acalabrutinib in ibrutinib-intolerant sufferers with relapsed/refractory power lymphocytic leukemia. Haematol. 2021;106:2364–73.
Choi MY, Widhopf GF, Ghia EM, Kidwell RL, Hasan MK, Yu J, et al. Part I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in sufferers with power lymphocytic leukemia. Cell Stem Cell. 2018;22:951–9.e3
Blombery P, Thompson ER, Lew TE, Tiong IS, Bennett R, Cheah CY, et al. Enrichment of BTK Leu528Trp mutations in sufferers with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance. Blood Adv. 2022;6:5589–92.
Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, et al. Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors. N. Engl J Med. 2022;386:735–43.
Searle E, Forconi F, Linton Okay, Danilov A, McKay P, Lewis D, et al. Preliminary findings from a first-in-human part 1a/b trial of NX-5948, a selective Bruton’s tyrosine kinase (BTK) degrader, in sufferers with relapsed/refractory B cell malignancies. Blood. 2023;142:4473.
Rogers KA, Flinn IW, McGarry C, Gou LC, Hassounah N, Woo J, et al. Part Ib examine of ianalumab (VAY736) and ibrutinib in sufferers with power lymphocytic leukemia (CLL) on ibrutinib remedy. Blood. 2020;136:13–4.
Desai P, Lonial S, Cashen A, Kamdar M, Blachly JS, Flinn IW, et al. P579: security, tolerability, pharmacokinetics, and preliminary antitumor exercise of Azd5991 in relapsed/refractory hematologic malignancies: a part 1 first-in-human examine. HemaSphere. 2023;7:e98838e7.
Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature. 2022;602:503–9.
Townsend W, Leong S, Shah M, Batten T, Tucker D, Pottinger B, et al. Time restricted publicity to a ROR1 focusing on bispecific T cell engager (NVG-111) results in sturdy responses in topics with relapsed refractory power lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Blood. 2023;142:329–329.
Perutelli F, Jones R, Griggio V, Vitale C, Coscia M. Immunotherapeutic methods in power lymphocytic leukemia: advances and challenges. Entrance Oncol. 2022;12:837531.
Wierda WG, Dorritie KA, Munoz J, Stephens DM, Solomon SR, Gillenwater HH, et al. Transcend CLL 004: part 1 cohort of lisocabtagene maraleucel (liso-cel) together with ibrutinib for sufferers with relapsed/refractory (R/R) power lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Blood. 2020;136:39–40.
Krämer I, Stilgenbauer S, Dietrich S, Böttcher S, Zeis M, Stadler M, et al. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017;130:1477–80.
van Gelder M, de Wreede LC, Bornhäuser M, Niederwieser D, Karas M, Anderson NS, et al. Lengthy-term survival of sufferers with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2017;52:372–80.
Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J, et al. Indications for allogeneic stem cell transplantation in power lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21:12–7.
Schetelig J, de Wreede LC, van Gelder M, Andersen NS, Moreno C, Vitek A, et al. Threat elements for remedy failure after allogeneic transplantation of sufferers with CLL: a report from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2017;52:552–60.
